Todas as fotos(1)



Erythropoietin human

EPO, recombinant, expressed in HEK 293 cells, suitable for cell culture

Número CAS:
Número MDL:

Nível de qualidade


fonte biológica



expressed in HEK 293 cells


≥95% (SDS-PAGE)


lyophilized powder


≤5.0 ng/mL ED50


endotoxin tested

peso molecular

dimer 36 kDa (glycosylated)


pkg of 10 μg

condição de armazenamento

avoid repeated freeze/thaw cycles


cell culture | mammalian: suitable


≤1 EU/μg

nº de adesão UniProt

temperatura de armazenamento


Gene Information

human ... EPO(2056)

Procurando produtos similares? Visit Guia de comparação de produtos

Categorias relacionadas

Descrição geral

EPO has been cloned from various species including human, murine, canine, and others. The mature proteins from the various species are highly conserved and exhibit greater than 80% amino acid sequence identity. EPO contains three N-linked glycosylation sites. The glycosylation of erythropoietin is required for the biological activities of erythropoietin in vivo.

Ações bioquímicas/fisiológicas

Erythropoietin (EPO), produced primarily by the kidney, is the primary regulatory factor of erythropoiesis. It promotes the proliferation, differentiation, and survival of the erythroid progenitors. Erythropoietin stimulates erythropoiesis by inducing growth and differentiation of burst forming units and colony forming units into mature red blood cells. EPO produced by kidney cells is increased in response to hypoxia or anemia. The biological effects of erythropoietin are mediated by the erythropoietin receptor, which binds EPO with high affinity and is a potent EPO antagonist.
Erythropoietin is a glycoprotein that is the principal regulator of red blood cell growth and differentiation.

Nota de preparo

Human EPO is expressed as a glycosylated 36 kDa monomer in human HEK 293 cells. Production in human HEK 293 cells offers authentic glycosylation. Glycosylation contributes to stability in cell growth media and other applications.

Nota de análise

The specific activity was determined by the dose-dependent stimulation of the proliferation of human TF-1 cells (human erythroleukemic indicator cell line).

Código de classe de armazenamento

13 - Non Combustible Solids



Ponto de fulgor (ºF)

Not applicable

Ponto de fulgor (ºC)

Not applicable

Certificado de análise

Certificado de origem

Lamia Lamrani et al.
Blood, 124(7), 1136-1145 (2014-06-22)
Thrombosis is common in patients suffering from myeloproliferative neoplasm (MPN), whereas bleeding is less frequent. JAK2(V617F), the main mutation involved in MPN, is considered as a risk factor for thrombosis, although the direct link between the mutation and hemostatic disorders
Léon Kautz et al.
Nature genetics, 46(7), 678-684 (2014-06-02)
Recovery from blood loss requires a greatly enhanced supply of iron to support expanded erythropoiesis. After hemorrhage, suppression of the iron-regulatory hormone hepcidin allows increased iron absorption and mobilization from stores. We identified a new hormone, erythroferrone (ERFE), that mediates
Mawadda Alnaeeli et al.
Diabetes, 63(7), 2415-2431 (2014-03-22)
Obesity-induced white adipose tissue (WAT) inflammation and insulin resistance are associated with macrophage (Mф) infiltration and phenotypic shift from "anti-inflammatory" M2-like to predominantly "proinflammatory" M1-like cells. Erythropoietin (EPO), a glycoprotein hormone indispensable for erythropoiesis, has biological activities that extend to
Hal E Broxmeyer
The Journal of experimental medicine, 210(2), 205-208 (2013-02-13)
Erythropoietin (EPO), a humoral regulator of erythropoiesis and replacement therapy for selected red blood cell disorders in EPO-deficient patients, has been implicated in a wide range of activities on diverse cell, tissue, and organ types. EPO signals via two receptors
Dhiraj Joshi et al.
Journal of vascular surgery, 60(1), 191-201 (2013-09-24)
Managing critical limb ischemia (CLI) is challenging. Furthermore, ischemic myopathy prevents good functional outcome after revascularization. Hence, we have focused on limiting the tissue damage rather than angiogenesis, which has traditionally been the motivation to develop nonsurgical treatments for CLI.


Hematopoietic Cytokines

Read article on hematopoietic cytokines and hematopoiesis


Induced Pluripotent Stem Cell Reprogramming Protocols

Stem cell reprogramming protocols to generate human induced pluripotent stem cells (iPSCs) including viral and non-viral RNA based methods.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica